FUNDAMENTALS · Fundamentals · NZ Healthcare

Fisher & Paykel Healthcare (FPH) Fundamentals 2026 — P/E 49.8x, Revenue Analysis | SniperIQ

Fisher & Paykel Healthcare (FPH) is a NZ-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of A

9.4B, trading at A
3.07 on the ASX. This SniperIQ fundamentals page covers Fisher & Paykel Healthcare's valuation (P/E 49.8x, P/B 11.0x), profitability (net margin 20.0%), revenue (NZD 2.4B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapA
9.4B
P/E (TTM)49.8x
Net Margin20.0%
Revenue (FY26)NZD 2.4B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Fisher & Paykel Healthcare's market cap?

Fisher & Paykel Healthcare (FPH) has a market capitalization of approximately A

9.4B, trading at A
3.07 on the ASX. Market cap moves with the live share price.

What is Fisher & Paykel Healthcare's P/E ratio?

Fisher & Paykel Healthcare's trailing twelve-month P/E ratio is 49.8x, with a price-to-book (P/B) of 11.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Fisher & Paykel Healthcare?

Fisher & Paykel Healthcare runs a net profit margin of 20.0%, a gross margin of 64.2%, and an operating margin of 28.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Fisher & Paykel Healthcare generate?

Fisher & Paykel Healthcare reported revenue of NZD 2.4B for fiscal year 2026, with net income of NZD 472M and earnings per share (EPS) of 0.8. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Fisher & Paykel Healthcare pay a dividend?

Fisher & Paykel Healthcare offers a trailing dividend yield of about 1.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Fisher & Paykel Healthcare financially healthy?

Fisher & Paykel Healthcare carries a debt-to-equity ratio of 0.07x and a current ratio of 2.31x, with a market beta of 0.89. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Fisher & Paykel Healthcare a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Fisher & Paykel Healthcare (FPH) the key facts are: market cap A

9.4B, P/E 49.8x, revenue NZD 2.4B, 52-week range 26.51-35.31. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Fisher & Paykel Healthcare's full fundamentals live

Get Fisher & Paykel Healthcare's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Guardant Health (GH) fundamentals · Joincare Pharmaceutical Group Industry (600380) fundamentals · Chengdu Kanghong Pharmaceutical Group (002773) fundamentals · TTY Biopharm (4105) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons